• Janusz Kochman, Zenon Huczek, Piotr Scisło, Maciej Dabrowski, Zbigniew Chmielak, Piotr Szymański, Adam Witkowski, Radosław Parma, Andrzej Ochala, Piotr Chodór, Krzysztof Wilczek, Krzysztof W Reczuch, Piotr Kubler, Bartosz Rymuza, Lukasz Kołtowski, Anna Scibisz, Radosław Wilimski, Eberhard Grube, and Grzegorz Opolski.
• First Department of Cardiology, Medical University of Warsaw, Warsaw, Poland. Electronic address: jkochman@wum.edu.pl.
• Am. J. Cardiol. 2014 Sep 1; 114 (5): 757-62.

AbstractThe aim of the study was to evaluate the transcatheter aortic valve replacement (TAVR) in high-risk patients with severe bicuspid aortic valve (BAV) stenosis and to compare the outcomes with a matched group of patients with tricuspid aortic valve. TAVR became an alternative treatment method in high-risk patients with symptomatic aortic stenosis; however, BAV stenosis is regarded as a relative contraindication to TAVR. The study population comprised 28 patients with BAV who underwent TAVR. BAV was diagnosed based on a transesophageal echocardiography. CoreValve and Edwards SAPIEN prostheses were implanted. The control group consisted of 84 patients (3:1 matching) with significant tricuspid aortic valve stenosis treated with TAVR. There were no significant differences between patients with and without BAV in device success (93% vs 93%, p = 1.0), risk of annulus rupture (0% in both groups), or conversion to cardiosurgery (4% vs 0%, respectively, p = 0.25). The postprocedural mean pressure gradient (11.5 ± 6.4 vs 10.4 ± 4.5 mm Hg, p = 0.33), aortic regurgitation grade ≥2 of 4 (32% vs 23%, p = 0.45), 30-day mortality (4% vs 7%, p = 0.68), and 1-year all-cause mortality (19% vs 18%, p = 1.00) did not differ between the groups. Echocardiography showed well-functioning valve prosthesis with a mean prosthetic valve area of 1.6 ± 0.4 cm(2) versus 1.7 ± 0.3 cm(2) (p = 0.73), a mean pressure gradient of 10.3 ± 5.4 versus 9.8 ± 2.8 mm Hg (p = 0.64), and aortic regurgitation grade ≥2 of 4 (22% vs 22%, p = 1.00) for the 2 groups. In conclusion, selected high-risk patients with BAV can be successfully treated with TAVR, and their outcomes are similar to those reported in patients without BAV.Copyright © 2014 Elsevier Inc. All rights reserved.

25 keywords...

hide…